Sponsors (12)
The bill balances loosening certain federal dispensing restrictions for medication abortion (potentially preserving easier access for patients and providers) against the risk of nullifying FDA approvals, which could remove a key treatment option, disrupt supply chains and care continuity, increase costs, create safety risks, and trigger legal and administrative burdens.
Women seeking medication abortion would face reduced federal regulatory barriers for certain abortion drugs, preserving easier access and fewer prescribing restrictions if existing FDA approvals remain in place.
Hospitals, clinics, and pharmacies would avoid new REMS-like dispensing restrictions, allowing more locations and providers to dispense medication and reducing administrative barriers to providing care.
Women seeking medication abortion would lose access to FDA-approved mifepristone if the bill nullifies its approval, removing a widely used, effective option for medication abortion.
Hospitals, clinics, pharmacies, and patients could face legal and supply disruptions that reduce availability and raise costs as manufacturers and distributors adjust to revoked approvals.
People seeking abortion may be pushed toward less-regulated or unsafe alternatives and experience disrupted continuity of care as clinicians navigate the absence of FDA-approved options.
Based on analysis of 2 sections of legislative text.
Introduced January 28, 2025 by Mary E. Miller · Last progress January 28, 2025
Prohibits the Department of Health and Human Services (including the FDA) from treating pregnancy as an illness when approving abortion drugs or when imposing or maintaining Risk Evaluation and Mitigation Strategies (REMS) for abortion drugs. Declares nullified any drug approvals that relied in whole or in part on treating pregnancy as an illness and explicitly includes the existing FDA approval of mifepristone among those voided.